NCT05201859View on ClinicalTrials.gov

Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 29, 2022

Primary Completion Date

February 15, 2025

Study Completion Date

February 15, 2026

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

Sintilimab

Sintilimab is a humanized monoclonal antibody against Programmed death 1(PD-1).

DRUG

Capecitabine

An oral anticancer agent that can be converted into 5-Fu in vivo.

Trial Locations (1)

510060

RECRUITING

Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER